Clinical trialPhase 2Completed
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 20 October 2023
- Ended
- 3 October 2025
- Enrollment
- 12 participants
- Sites
- 4
- Primary outcomes
- Percentage of Participants With Objective Response Rate
- Sponsor type
- Industry
- Results posted
- 25 August 2026
- Last update
- 25 August 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 25 August 2026
- ORR
- Percentage of Participants With Objective Response RateNeuroendocrine Tumors: 8.3 (0.2 to 38.5), n = 12Values: Percent of participants, 95% Confidence IntervalTime frame: From the start of study treatment to radiographically confirmed disease progression (PD) per RECIST v1.1, assessed at screening, every 6 weeks (±7 days) for the first 12 weeks, and every 12 weeks (±7 days) thereafter, up to 22 months.No analysis posted for this outcome (outcome 1)
- Participants
- Neuroendocrine Tumors: 12 started, 1 completed
- Serious adverse events
- Neuroendocrine Tumors: 4 of 12Participants with at least one serious adverse event, of those at risk, as posted
6 secondary outcomes
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-R…
- Neuroendocrine Tumors 100, n=12 [Percent of participants]
- Duration of Response (DOR)
- Neuroendocrine Tumors NA (NA to NA), n=1 [median Months, 95% Confidence Interval]
- DCR · Disease Control Rate (DCR)
- Neuroendocrine Tumors 50.0 (21.1 to 78.9), n=12 [Percent of participants, 95% Confidence Interval]
- Time to Response (TTR)
- Neuroendocrine Tumors 1.51 (NA to NA), n=12 [median Months, 95% Confidence Interval]
- PFS · Progression-free Survival(PFS)
- Neuroendocrine Tumors 10.0 (5.4 to NA), n=12 [median Months, 95% Confidence Interval]
- OS · Overall Survival(OS)
- Neuroendocrine Tumors NA (9.7 to NA), n=12 [median Months, 95% Confidence Interval]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors
Detailed description public domain (ClinicalTrials.gov)
This is a prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus and patients with functional or non-functional, well-differentiated, locally advanced unresectable in metastatic NETs of the GI tract, lung, or pancreas.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Percentage of Participants With Objective Response Rate [From the start of study treatment to radiographically confirmed disease progression (PD) per RECIST v1.1, assessed at screening, every 6 weeks (±7 days) for the first 12 weeks, and every 12 weeks (±7 days) thereafter, up to 22 months.]. Number, Percent of participants (95% Confidence Interval). Neuroendocrine Tumors (n=12): 8.3 (0.2 to 38.5).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events. [From first dose of study treatment through end of treatment (estimated up to 18 months) plus safety follow-up of 30 days after the last dose.]. Number, Percent of participants. Neuroendocrine Tumors (n=12): 100.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Duration of Response (DOR) [From first documented response (CR or PR) to radiographically confirmed disease progression (PD) per RECIST v1.1 or death from any cause, assessed at screening, every 6 weeks for the first 12 weeks, and every 12 weeks thereafter, up to 22 months]. Median, Months (95% Confidence Interval). Neuroendocrine Tumors (n=1): NA (NA to NA) [The Duration of Response (DOR) was evaluable in only one subject, and the median could not be estimated due to the absence of events.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Disease Control Rate (DCR) [From the start of study treatment to radiographically confirmed disease progression (PD) per RECIST v1.1, assessed at screening, every 6 weeks for the first 12 weeks, and every 12 weeks thereafter, up to 22 months]. Number, Percent of participants (95% Confidence Interval). Neuroendocrine Tumors (n=12): 50.0 (21.1 to 78.9).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Time to Response (TTR) [From the first dose of study treatment to the initial documentation of complete response (CR) or partial response (PR) per RECIST v1.1 , assessed at screening, every 6 weeks for the first 12 weeks, and every 12 weeks thereafter, up to 22 months]. Median, Months (95% Confidence Interval). Neuroendocrine Tumors (n=12): 1.51 (NA to NA) [The 95% confidence interval was not estimable due to the limited number of responders (N=1).].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-free Survival(PFS) [From first dose of study treatment until the date of first documented disease progression or death from any cause, whichever occurs first, assessed every 6 weeks for the first 12 weeks and every 12 weeks thereafter, up to approximately 21 months]. Median, Months (95% Confidence Interval). Neuroendocrine Tumors (n=12): 10.0 (5.4 to NA) [The upper bound of the confidence interval could not be estimated because the survival curve did not reach the upper threshold due to a limited number of events.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival(OS) [From first dose of study treatment until the date of death from any cause, assessed approximately every 12 weeks following the end-of-treatment visit, up to approximately 24 months.]. Median, Months (95% Confidence Interval). Neuroendocrine Tumors (n=12): NA (9.7 to NA) [The median and the upper limit of the 95% confidence interval were not estimable due to a limited number of events and a high proportion of censored patients.].